Literature DB >> 22580519

Anxiogenic effect of CCK8s in the ventral hippocampus of rats: possible involvement of GABA(A) receptors.

Akbar Hajizadeh Moghaddam1, Robabeh Sadat Hosseini, Ali Roohbakhsh.   

Abstract

Cholecystokinin (CCK) as an important neuropeptide in the brain has been implicated in the modulation of anxiety. The effects of this neurotransmitter on anxiety-like behavior in the ventral hippocampus have not been evaluated yet. Moreover, some evidences show a functional interaction between GABA and CCK in the nervous system. Bilateral injections of three doses of CCK8s (0.01, 0.05 and 0.1 μg/rat) into the ventral hippocampus decreased percentage of open arm time (%OAT) and open arm entries (%OAE) that are representative of anxiogenic-like behavior in the elevated plus-maze test of anxiety. Bilateral injections of LY225910, a selective CCK(2) receptor antagonist, at the doses of 0.01, 0.1 and 0.5 μg/rat did not change anxiety-related parameters. Administration of muscimol, a selective GABA(A) receptor agonist, at the doses of 0.001, 0.005 and 0.01 μg/rat produced dose dependent increase in %OAT and %OAE indicating an anxiolytic-like effect, while administration of bicuculline, a selective GABA(A) receptor antagonist, at the doses of 0.1, 0.2 and 0.5 μg/rat decreased %OAT and %OAE showing that this drug promoted anxious behavior of the rats. Co-administration of bicuculline (0.2 μg/rat) with CCK8s decreased the anxiogenic effects of CCK8s. Furthermore, co-administration of LY225910 (0.5 μg/rat) with muscimol increased the anxiolytic effect of muscimol at the dose of 0.001 μg/rat. The results of this study suggest that both CCK and GABAergic system have important and opposite roles in the modulation of anxiety-like behavior in the ventral hippocampus of rats and they may have a complex interaction in the ventral hippocampus to modulate anxiety-related behavior.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580519     DOI: 10.1016/s1734-1140(12)70729-6

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  2 in total

1.  Identification of a role for the ventral hippocampus in neuropeptide S-elicited anxiolysis.

Authors:  Julien Dine; Irina A Ionescu; Jens Stepan; Yi-Chun Yen; Florian Holsboer; Rainer Landgraf; Matthias Eder; Ulrike Schmidt
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

Review 2.  Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.

Authors:  Santiago J Ballaz; Michel Bourin
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.